A detailed history of Nuveen Asset Management, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 120,896 shares of ACLX stock, worth $9.13 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
120,896
Previous 121,911 0.83%
Holding current value
$9.13 Million
Previous $6.73 Million 50.06%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$50.91 - $86.61 $51,673 - $87,909
-1,015 Reduced 0.83%
120,896 $10.1 Million
Q2 2024

Aug 09, 2024

SELL
$49.74 - $66.98 $3.23 Million - $4.35 Million
-64,872 Reduced 34.73%
121,911 $6.73 Million
Q1 2024

May 13, 2024

SELL
$51.85 - $73.49 $4.81 Million - $6.82 Million
-92,843 Reduced 33.2%
186,783 $13 Million
Q4 2023

Feb 14, 2024

BUY
$31.75 - $57.99 $1.12 Million - $2.05 Million
35,433 Added 14.51%
279,626 $15.5 Million
Q3 2023

Nov 14, 2023

BUY
$31.51 - $37.4 $224,571 - $266,549
7,127 Added 3.01%
244,193 $8.76 Million
Q2 2023

Aug 14, 2023

BUY
$27.49 - $46.9 $3.81 Million - $6.5 Million
138,577 Added 140.7%
237,066 $7.5 Million
Q1 2023

May 15, 2023

BUY
$26.92 - $33.94 $233,827 - $294,802
8,686 Added 9.67%
98,489 $3.03 Million
Q4 2022

Feb 14, 2023

SELL
$17.18 - $33.0 $245,931 - $472,395
-14,315 Reduced 13.75%
89,803 $2.78 Million
Q3 2022

Nov 14, 2022

BUY
$16.67 - $22.04 $1.52 Million - $2.01 Million
91,236 Added 708.24%
104,118 $1.95 Million
Q2 2022

Aug 15, 2022

BUY
$7.21 - $24.43 $1,232 - $4,177
171 Added 1.35%
12,882 $233,000
Q1 2022

May 16, 2022

BUY
$12.97 - $19.14 $164,861 - $243,288
12,711 New
12,711 $178,000

Others Institutions Holding ACLX

About Arcellx, Inc.


  • Ticker ACLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,819,200
  • Market Cap $3.31B
  • Description
  • Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...
More about ACLX
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.